LCMS-8050 Mass Spectrometer Increases Quality Analysis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

LCMS-8050 Mass Spectrometer Increases Quality Analysis


Pharmaceutical Technology
Volume 37, Issue 10, pp. 18
Untitled Document

The LCMS-8050 triple quadrupole mass spectrometer can perform both positive and negative ion analysis in a single run for faster throughput. The LCMS-8050 achieves high sensitivity through a patented ion optics system, a designed heated ESI probe, and UFsweeper III Collision Cell. The LCMS-8050 offers multiple reaction monitoring (MRM) speeds of 555 ch/sec and maintains spectrum quality, sensitivity, and accuracy at scan speeds up to 30,000 μ/sec. The Synchronized Survey Scan function allows users to obtain MRM data while simultaneously performing qualitative MS/MS scans. The LCMS-8050 provides 5-millisecond polarity switching and maintains ion intensity during polarity switching at high speeds. The ion source features a cable-free, tubeless housing when switching from ESI to APCI or dual-ionization mode.

Shimadzu Scientific Instruments

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here